Skip to main content

Advertisement

Fig. 4 | Clinical Epigenetics

Fig. 4

From: Histone methyltransferase SMYD2: ubiquitous regulator of disease

Fig. 4

The nonhistone substrates of SMYD2 involved in cancer and other disease. Several nonhistone proteins are methylated by SMYD2 during cancer formation, including p53, RB, PTEN, ERĪ±, PARP1, ALK, MAPKAPK3, and HSP90AB1. SMYD2 methylates and activates p65 and STAT3 to regulate autosomal dominant polycystic kidney disease. BMPR2 methylated by SMYD2 to activate SMAD1/5 signaling. Methylation on substrates always cross-talks with other posttranslational modifications, especially phosphorylation, to affect signaling pathways and target genes related to cancer and other disease

Back to article page